2 Information about finerenone

Marketing authorisation indication

2.1 Finerenone (Kerendia, Bayer) is indicated 'for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for finerenone.


2.3 The list price of finerenone is £36.68 for 28 tablets, for both the 10‑mg and 20‑mg doses. The daily cost of treatment is £1.31 (BNF online, accessed January 2023). Costs may vary in different settings because of negotiated procurement discounts.

  • National Institute for Health and Care Excellence (NICE)